Latest Research And Development News

Page 6 of 115
Lithium Universe ended September with A$429,000 in cash and estimated funding of just 0.82 quarters after reporting no exploration, development or production activity. The company says it is reducing operating expenditure and assessing further funding options.
Maxwell Dee
Maxwell Dee
30 Oct 2026
West Cobar Metals is preparing its first dedicated scandium drilling campaign at Salazar, with the programme expanded to include the Benriach prospect. But the company ended September with A$918,000 cash and an estimated 1.72 quarters of funding at the quarter’s reported expenditure rate.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Parkway Corporate delivered record quarterly revenue of $7.71 million and $1.08 million in operating cash flow as its mine dewatering contract expanded to about $2.1 million. The company also advanced its Queensland brine project, although its next test is turning approvals and technology development into funded commercial infrastructure.
Victor Sage
Victor Sage
30 Oct 2026
Miramar Resources has reported a maiden Inferred gold resource of 39,764 ounces at its 80%-owned Gidji JV near Kalgoorlie and secured $1.25 million to fund follow-up work. The resource is shallow and potentially expandable, but remains entirely Inferred and unsupported by metallurgical test work.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Chimeric Therapeutics has stopped enrolment and dosing in its CHM-2101 CAR-T trial after a safety review found the highest dose unsafe. With $1.35 million in cash, suspended securities and uncertain creditor negotiations, the company is now pursuing a possible recapitalisation while preserving a preclinical CDH17 pathway.
Ada Torres
Ada Torres
29 Oct 2026
Vectus Biosystems has secured FDA acceptance of a pre-IND Type B meeting for VB0004, a key regulatory step for its idiopathic pulmonary fibrosis programme. The biotech ended September with $410,000 in cash and reported estimated funding for just 1.33 quarters of operations.
Ada Torres
Ada Torres
29 Oct 2026
Knosys has moved its Libero library platform into active US commercialisation, identifying near-term sales opportunities while preparing for its first customer engagements. The push comes as ARR slips to A$8.7 million and a timing-affected quarter leaves the company with 2.03 quarters of estimated funding.
Victor Sage
Victor Sage
29 Oct 2026
Tissue Repair has increased its US Phase III chronic wound trial to approximately 112 randomised patients while shifting focus towards an April 2027 FDA 510(k) submission. The company also reported $4.74 million in cash, Australian availability of all three TR Pro+ formats and a planned $1 million share buy-back.
Ada Torres
Ada Torres
29 Oct 2026
AnteoTech reported a quarter of technical milestones and commercial discussions across its battery and life sciences businesses, including new agreements with Xerabrid and Airspeeder. The company ended September with about A$11 million in cash, although an inconsistency in the Appendix 4C reconciliation needs clarification.
Victor Sage
Victor Sage
29 Oct 2026
InFocus has reduced quarterly operating cash outflow by 40% while advancing Codexa and securing a conditional first customer for its overseas real-money gaming platform. The USD 2.4 million minimum fee commitment is substantial for the company, but it depends on development, licensing and launch milestones that have not yet been completed.
Sophie Babbage
Sophie Babbage
29 Oct 2026
BlinkLab has reported 82% sensitivity and 83% specificity from an exploratory ADHD study in 208 children, while preparing a US regulatory program for a second product. Its autism diagnostic remains on track for pivotal study completion this quarter, with A$16.2 million in cash at 30 September.
Victor Sage
Victor Sage
29 Oct 2026
ION Video has moved its video technology into a series of externally funded and independently assessed validation programs, including an AWS proof of concept and a potential Nordic data centre trial worth at least A$1 million. The company ended September with A$3.522 million in cash, but remains pre-revenue and expects higher spending as commercialisation efforts expand.
Sophie Babbage
Sophie Babbage
29 Oct 2026

Browse the archive

Full archive